Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

2021187 citationsJournal Articlegold Open Access

Authors

Zhi Peng · Peking University

Tianshu Liu · Sun Yat-sen University

Jia Wei · Nanjing Drum Tower Hospital

Airong Wang · Weihai Municipal Hospital

Yifu He · Anhui Provincial Hospital

Liuzhong Yang · Xinxiang Medical University

Xizhi Zhang ·

Abstract

RC48 showed promising activity with manageable safety, suggesting potential application in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.

Topics & Keywords

Gastric Cancer Management and Outcomes HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Communications

Volume 41, Issue 11, pp. 1173-1182

DOI: 10.1002/cac2.12214

Field-Weighted Citation Impact: 18.96